Equities research analysts expect Perrigo Company PLC (NYSE:PRGO) to report sales of $1.18 billion for the current fiscal quarter, Zacks Investment Research reports. Twelve analysts have made estimates for Perrigo’s earnings. The lowest sales estimate is $1.16 billion and the highest is $1.19 billion. Perrigo reported sales of $1.28 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 7.8%. The company is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, February 27th.

According to Zacks, analysts expect that Perrigo will report full-year sales of $4.72 billion for the current year, with estimates ranging from $4.69 billion to $4.73 billion. For the next year, analysts expect that the business will report sales of $4.77 billion, with estimates ranging from $4.58 billion to $4.90 billion. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for Perrigo.

A number of equities research analysts recently commented on the company. Royal Bank of Canada set a $50.00 target price on Perrigo and gave the stock a “hold” rating in a report on Friday, January 4th. Wells Fargo & Co set a $46.00 target price on Perrigo and gave the stock a “hold” rating in a report on Sunday, December 30th. Morgan Stanley set a $67.00 target price on Perrigo and gave the stock a “hold” rating in a report on Sunday, December 30th. Leerink Swann decreased their price target on Perrigo from $70.00 to $56.00 in a report on Monday, December 24th. Finally, Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the company a “buy prgo” rating in a report on Thursday, December 20th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company’s stock. Perrigo presently has a consensus rating of “Hold” and a consensus price target of $77.36.

Several institutional investors and hedge funds have recently modified their holdings of PRGO. FMR LLC increased its position in shares of Perrigo by 114.3% during the third quarter. FMR LLC now owns 11,080,094 shares of the company’s stock worth $784,471,000 after purchasing an additional 5,909,969 shares in the last quarter. Iridian Asset Management LLC CT purchased a new stake in shares of Perrigo during the third quarter worth approximately $136,248,000. Ceredex Value Advisors LLC increased its position in shares of Perrigo by 132.0% during the third quarter. Ceredex Value Advisors LLC now owns 2,828,159 shares of the company’s stock worth $200,234,000 after purchasing an additional 1,609,009 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Perrigo by 3,574.9% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,430,805 shares of the company’s stock worth $37,000 after purchasing an additional 1,391,870 shares in the last quarter. Finally, First Eagle Investment Management LLC purchased a new stake in shares of Perrigo during the third quarter worth approximately $47,818,000. Hedge funds and other institutional investors own 85.72% of the company’s stock.

Shares of Perrigo stock traded up $0.35 on Monday, reaching $48.95. 1,054,954 shares of the stock were exchanged, compared to its average volume of 1,527,917. The company has a quick ratio of 1.26, a current ratio of 1.85 and a debt-to-equity ratio of 0.54. Perrigo has a twelve month low of $36.28 and a twelve month high of $90.72. The company has a market capitalization of $6.65 billion, a price-to-earnings ratio of 9.93, a price-to-earnings-growth ratio of 1.78 and a beta of 1.31.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 19th. Investors of record on Friday, March 1st will be given a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 1.55%. The ex-dividend date is Thursday, February 28th. Perrigo’s payout ratio is 15.42%.

About Perrigo

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

Featured Article: What is a capital gain?

Get a free copy of the Zacks research report on Perrigo (PRGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.